title: The effect of oxidized low-density lipoprotein combined with adriamycin on the proliferation of Eca-109 cell line.
abstract: BACKGROUND
  The purpose of this study was to identify the affect on the proliferation Eca-109 cells treated with oxidized low-density lipoprotein (ox-LDL) combined with adriamycin (ADM).
  
  
  METHODS
  Eca-109 cell were cultured in the presence of oxLDL/ADM, and cell proliferation tested by MTT and cell apoptosis was monitored by the proportion of apoptosis and cell cycle by flow cytomester. We simultaneously evaluated the level of associated- apoptosis Bcl-2, Bax, and Caspase-3 gene mRNA and protein.
  
  
  RESULTS
  OxLDL were cytotoxic and activate apoptosis. OxLDL combined with ADM significant enhanced the proportion rate of apoptosis on a time and dose dependency. The expressions of the inhibiting apoptosis Bcl-2 gene mRNA and protein were down regulated, whereas, the expressions of the promoting apoptosis Bax, and Caspase-3 genes mRNA and protein were up regulation.
  
  
  CONCLUSIONS
  These results suggested that oxLDL have cytotoxicity and activate apoptosis on the Eca-109 cells. OxLDL combined with ADM have a synergistic effect on the apoptosis induced Eca-109 cells. Furthermore, oxLDL may contribute to the improvement of clinical chemotherapy of cancer need to make further investigation.
authors.affiliation: Qilu Hospital, Shandong University, Jinan, P.R. China. haoli2003611@163.com
authors.forename: Hao
authors.initials: H
authors.lastname: Li
authors.forename: Qing D
authors.initials: QD
authors.lastname: Li
authors.forename: Ping Zhi
authors.initials: PZ
authors.lastname: Wang
authors.forename: Mei Shu
authors.initials: MS
authors.lastname: Wang
authors.forename: Jia
authors.initials: J
authors.lastname: Cui
authors.forename: Tao Yu
authors.initials: TY
authors.lastname: Diao
authors.forename: Qing Hui
authors.initials: QH
authors.lastname: Li
mesh_terms: D017209:Apoptosis; D002294:Carcinoma, Squamous Cell; D053148:Caspase 3 / Q000235:genetics / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D048430:Cell Shape / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D004357:Drug Synergism; D004938:Esophageal Neoplasms; D006801:Humans; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
chemical_list: D008077:Lipoproteins, LDL; D019253:Proto-Oncogene Proteins c-bcl-2; C099252:oxidized low density lipoprotein; D004317:Doxorubicin; C505407:CASP3 protein, human; D053148:Caspase 3